Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug (original) (raw)
Rowley, J. D. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature243, 290–293 (1973). ArticleCASPubMed Google Scholar
Nowell, P. C. & Hungerford, D. A. A minute chromosome in human chronic granulocytic leukemia. Science132, 1497 (1960). Google Scholar
Daley, G. Q., Van Etten, R. A. & Baltimore, D. Induction of chronic myelogenous leukemia in mice by the p210_Bcr/Abl_ gene of the Philadelphia chromosome. Science247, 824–830 (1990). ArticleCASPubMed Google Scholar
Kelliher, M. A. et al. Induction of chronic myelogenous leukemia in mice by the v-Abl and Bcr/Abl. Proc. Natl Acad. Sci. USA87, 6649–6653 (1990). ArticleCASPubMedPubMed Central Google Scholar
Heisterkamp, N. et al. Acute leukaemia in Bcr/Abl transgenic mice. Nature344, 251–253 (1990). ArticleCASPubMed Google Scholar
Lugo, T. G. et al. Tyrosine kinase activity and transformation potency of Bcr–Abl oncogene products. Science247, 1079–1082 (1990). ArticleCASPubMed Google Scholar
Lipinsky, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods44, 235–249 (2001). Article Google Scholar
Teague, S. et al. The design of leadlike combinatorial libraries. Angew. Chem. Int. Edn Eng.38, 3743–3748 (1999). ArticleCAS Google Scholar
Zimmermann, J. et al. (Phenylamino)pyrimidine (PAP) derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors. Bioorg. Med. Chem. Lett.6, 1221–1226 (1996). ArticleCAS Google Scholar
Zimmermann, J. et al. Potent and selective inhibitors of the ABL-kinase: phenylaminopyrimidine (PAP) derivatives. Bioorg. Med. Chem. Lett.7, 187–192 (1997). ArticleCAS Google Scholar
Zimmerman, J., Furet, P. & Buchdunger, E. STI571. A new treatment modality for CML. ACS Symp. Ser.796, 245–259 (2001). Article Google Scholar
Schindler, T. et al. Structural mechanism for STI571 inhibition of Abelson tyrosine kinase. Science289, 1938–1942 (2000).The first description of the structural interactions between Glivec and ABL using crystallographic studies. Provided an important insight into potential mechanisms of resistance. ArticleCASPubMed Google Scholar
Okuda, K. et al. ARG tyrosine kinase activity is inhibited by STI571. Blood97, 2440–2448 (2001). ArticleCASPubMed Google Scholar
Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr_–_Abl positive cells. Nature Med.2, 561–566 (1996).The first study to document the strong efficacy of Glivec inin vitroandin vivomodels of BCR–ABL-positive leukaemias. ArticleCASPubMed Google Scholar
Carroll, M. et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR–ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood90, 4947–4952 (1997). CASPubMed Google Scholar
Beran, M. et al. Selective inhibition of cell proliferation and BCR–ABL phosphorylation in acute lymphoblastic leukemia cells expressing _M_r 190,000 BCR–ABL protein by a tyrosine kinase inhibitor (CGP 57148). Clin. Cancer Res.4, 1661–1672 (1998). CASPubMed Google Scholar
Gambacorti-Passerini, C. et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol. Dis.23, 380–394 (1997). ArticleCASPubMed Google Scholar
Deininger, M. et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR–ABL-positive cells. Blood90, 3691–3698 (1997). CASPubMed Google Scholar
Dan, S., Naito, M. & Tsuruo, T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148B. Cell Death Differ.5, 710–715 (1998). ArticleCASPubMed Google Scholar
Le Coutre, P. et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl Cancer Inst.91, 163–168 (1999). ArticleCASPubMed Google Scholar
Wolff, N. C. & Ilaria, R. L. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood98, 2808–2816 (2001). ArticleCASPubMed Google Scholar
Sillaber, C. et al. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood95, 2118–2125 (2000). CASPubMed Google Scholar
Horita, M. et al. Blockade of the Bcr–Abl kinase activity induces apoptosis of chronic myeloid leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of BCL-XL . J. Exp. Med.191, 977–984 (2000). ArticleCASPubMedPubMed Central Google Scholar
Oda, T. et al. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J. Biol. Chem.269, 22925–22928 (1994). CASPubMed Google Scholar
Jonuleit, T. et al. Bcr–Abl kinase downregulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood96, 1933–1939 (2000). CASPubMed Google Scholar
Gesbert, F. et al. BCR/ABL regulates expression of the cyclin dependent kinase inhibitor p27Kip1 through the PI3K/AKT pathway. J. Biol. Chem.50, 39223–39230 (2000). Article Google Scholar
Gaston, I. et al. Abl kinase but not PI3-kinase links to the cytoskeletal defects in Bcr–Abl transformed cells. Exp. Hematol.28, 77–86 (2000). ArticleCASPubMed Google Scholar
Druker, B. J. et al. Activity of a specific inhibitor of the BCR–ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med.344, 1038–1042 (2001).The first clinical results with Glivec in CML, documenting a high level of efficacy, low level of toxicity and describing the dose–response relationship. These results confirm the crucial role of BCR–ABL in the pathophysiology of CML. ArticleCASPubMed Google Scholar
Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med.344, 1031–1037 (2001). ArticleCASPubMed Google Scholar
Peng, B. et al. Clinical investigation of the PK/PD relationship for Glivec (STI571): a novel inhibitor of signal transduction. Proc. Am. Soc. Clin. Oncol.20, 280 (2001). Google Scholar
Kantarjian, H. et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med.346, 645–652 (2002). ArticleCASPubMed Google Scholar
Talpaz, M. et al. Glivec™ (imatinib mesylate) induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase 2 study. Blood99, 1928–1937 (2002). ArticleCASPubMed Google Scholar
Sawyers, C. et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a Phase II study. Blood99, 3530–3539 (2002). ArticleCASPubMed Google Scholar
Weisberg, E. & Griffin, J. Mechanism of resistance to the Abl tyrosine kinase inhibitor STI571in BCR/ABL transformed hematopoietic cell lines. Blood95, 3498–3505 (2000). CASPubMed Google Scholar
Mahon, F. et al. Selection and characterization of BCR–ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood96, 1070–1079 (2000). CASPubMed Google Scholar
Le Coutre, P. et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood95,1758–1766 (2000). CASPubMed Google Scholar
Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification. Science293, 876–880 (2001).This study describes potential mechanisms of resistance in CML in clinical samples from treated patients. ArticleCASPubMed Google Scholar
Gorre, M. E. et al. Roots of clinical resistance to STI-571 cancer therapy. Science293, 2163a (2001). Article Google Scholar
Barthe, C. et al. Roots of clinical resistance to STI-571 cancer therapy. Science293, 2163a (2001). Article Google Scholar
Hochhaus, A. et al. Roots of clinical resistance to STI-571 cancer therapy. Science293, 2163a (2001). Article Google Scholar
Von Bubnoff, N. et al. BCR_–_ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet359, 487–491 (2002). ArticleCASPubMed Google Scholar
Manley, P. W. et al. Molecular interactions between Gleevec™ and isoforms of the c-Abl kinase. Proc. Am. Assoc. Cancer Res. 4196 (2002).
Gambacorti-Passerini, C. et al. α1 Acidic glycoprotein (AGP) binds, inhibits and causes in vivo resistance of human BCR–ABL+ leukemic cells to STI571. J. Natl Cancer Inst.92, 1641–1650 (2000). ArticleCASPubMed Google Scholar
Jorgensen, H. G. et al. α1-Acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood99, 713–715 (2002). ArticleCASPubMed Google Scholar
Hofmann, W. K. et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet359, 481–486 (2002). ArticleCASPubMed Google Scholar
Druker, B. STI571 (Gleevec/Glivec, imatinib) versus interferon (IFN)+ cytarabine as initial therapy for patients with CML: results of a randomized study. Proc. Am. Soc. Clin. Oncol. 1 (2002).
Buchdunger, E. et al. The Abl protein-tyrosine kinase inhibitor, STI571, inhibits in vitro signal transduction mediated by c-Kit and PDGF receptors. J. Pharmacol. Exp. Ther.295, 139–145 (2000). CASPubMed Google Scholar
Heinrich, M. C. et al. Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood96, 925–932 (2000). CASPubMed Google Scholar
Hirota, S. et al. Gain of function mutations of c-Kit in human gastrointestinal stromal tumors. Science279, 577–580 (1998).This study establishes the importance of c-KIT signalling in the pathogenesis of GIST tumours. ArticleCASPubMed Google Scholar
Lasota, J. et al. Mutations in exons 9 and 13 of Kit gene are rare events in gastrointestinal stromal tumors. A study of two hundred cases. Am. J. Pathol.157, 1091–1095 (2000). ArticleCASPubMedPubMed Central Google Scholar
Lux, M. L. et al. Kit extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am. J. Pathol.156, 791–795 (2000). ArticleCASPubMedPubMed Central Google Scholar
Rubin, B. P. et al. Kit activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res.61, 8118–8121 (2001). CASPubMed Google Scholar
Heinrich, M. C. et al. STI571 inhibits the kinase activity of wild type and juxtamembrane c-Kit mutants but not the exon 17 D816V mutations associated with mastocytosis. Blood96, 4459 (2000). Google Scholar
Tuveson, D. A. et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene20, 5054–5058 (2001). ArticleCASPubMed Google Scholar
Joensuu, H. et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with metastatic gastrointestinal stromal tumor. N. Engl. J. Med.344, 1052–1056 (2001).A proof-of-concept report of the efficacy of Glivec in KIT-expressing GIST, and rationale for further development in this indication, as well as in other solid tumours that express KIT. ArticleCASPubMed Google Scholar
Van Oosterom, A. T. et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors, a phase I study. Lancet358, 1421–1423 (2001). ArticleCASPubMed Google Scholar
Blanke, C. D. et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTs) expressing c-KIT (CD117). Proc. Am. Soc. Clin. Oncol.20, 1 (2001). Google Scholar
Heinrich, M. C. et al. Inhibition of Kit kinase activity: a novel molecular approach to the treatment of Kit-positive malignancies. J. Clin. Oncol.20, 1692–1703 (2002).An excellent review of KIT as a target for anticancer therapy. ArticleCASPubMed Google Scholar
Krystal, G. W., Hines, S. & Organ, C. Autocrine growth of small cell lung cancer mediated by co-expression of c-kit and stem cell factor. Cancer Res.56, 370–376 (1996). CASPubMed Google Scholar
Krystal, G. W., Carlson, P. & Litz, J. Induction of apoptosis and inhibition of small cell lung cancer growth by the quinoxaline tyrophostins. Cancer Res.57, 2203–2208 (1997). CASPubMed Google Scholar
Krystal, G. W. et al. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin. Cancer Res.6, 3319–3326 (2000). CASPubMed Google Scholar
Wang, W. L. et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer lines by the novel tyrosine kinase inhibitor STI571. Oncogene19, 3521–3528 (2000). ArticleCASPubMed Google Scholar
Buchdunger, E. et al. Effects of a selective inhibitor of the Abl tyrosine-kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res.56, 100–104 (1996). CASPubMed Google Scholar
Östman, A. & Heldin, C. H. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv. Cancer Res.80, 1–38 (2001). ArticlePubMed Google Scholar
Nistér, M. et al. Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. J. Biol. Chem.266, 16755–16763 (1991). PubMed Google Scholar
Kilic, T. et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyridine class. Cancer Res.60, 5143–5150 (2000). CASPubMed Google Scholar
Shimizu, A. et al. The dermatofibrosarcoma protuberans-associated collagen type 1α/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res.59, 3719–3723 (1999). CASPubMed Google Scholar
Greco, A. et al. Growth inhibitory effect of STI571 on cells transformed by the COL1A/PDGFB rearrangement. Int. J. Cancer92, 354–360 (2001). ArticleCASPubMed Google Scholar
Sjöblom, T. et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res.61, 5778–5783 (2001). PubMed Google Scholar
Awan, R. A. et al. Patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans (DFSP) may respond to imatinib (STI571, Gleevec). Proc. Am. Soc. Clin. Oncol. 1637 (2002).
Jousset, C. et al. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL–PDGFRβ oncoprotein. EMBO J.16, 69–82 (1997). ArticleCASPubMedPubMed Central Google Scholar
Tomasson, M. H. et al. TEL/PDGFβR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. Blood93, 1707–1714 (1999). CASPubMed Google Scholar
Apperley, J. F. et al. Chronic myeloproliferative diseases with t(5:12) and a PDGFRB fusion gene: complete cytogenetic remission with STI571. Blood98, 726A (2001).A proof-of-concept study of the efficacy of Glivec in a PDGFR-driven malignancy. Google Scholar
Gullberg, D. et al. α1 Integrin-mediated collagen gel contraction is stimulated by PDGF. Exp. Cell Res.186, 264–272 (1990). ArticleCASPubMed Google Scholar
Rodt, S. A. et al. A novel physiologic role for platelet-derived growth factor-BB in rat dermis. J. Physiol. (Lond.)495, 193–200 (1996). ArticleCAS Google Scholar
Heuchel, R. et al. Platelet-derived growth factor receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3 kinase signaling. Proc. Natl Acad. Sci. USA.20, 11410–11415 (1999). Article Google Scholar
Pietras, K. et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res.61, 2929–2934 (2001). CASPubMed Google Scholar
Hellström, M. et al. Role of PDGF-B and PDGFR-β in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Exp. Cell Res.186, 264–272 (1999). Google Scholar
Reinmuth, N. et al. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J.15, 1239–1241 (2001). ArticleCASPubMed Google Scholar
Wang, D. et al. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res.59, 1464–1472 (1999). CASPubMed Google Scholar
Buchdunger, E., O'Reilly, T. & Wood, J. Pharmacology of imatinib (STI571). Eur. J. Cancer (in the press).
Uehara, H. et al. Blockade of PDGF-R signaling by STI571 inhibits angiogenesis and growth of human prostate cancer cells in the bone of nude mice. Proc. Am. Assoc. Cancer Res. 2192 (2001).